remission of lymphoma and recovery of SOS. Conclusions: Cisplatin was often substituted by oxaliplatin inside the DHAP protocol in order to avoid renal impairment. Pre-operative oxali- platin in hepatic metastases of colorectal cancer leads to asymp- tomatic damage of sinusoidal endothelial cells in the liver. Our first hypothesis is that oxaliplatin provokes frailty of liver and condi- tioning of ASCT to lead to SOS. Early recognition of SOS is pri- mordially linked to the benefice of early treatment by defibrotide. We want to warn about the probable association of oxaliplatin before ASCT and SOS. In some French centers, this led to switch oxaliplatin by carboplatin in DHAP for patients eligible to ASCT. No grant. Keywords: ASCT, SOS, oxaliplatin, lymphoma, CT, cellular therapy CT-192 Autologous CD19-CAR T-Cells for the Treatment of Acute Lymphoblastic Leukemia in Pediatric and Young Adult Patients: An initial Report from an Institutional Phase I/II Study Aimee Talleur  , 1 Amr Qudeimat, 1 Timothy Lockey, 2 Alisha Gaboriault, 1 Deanna Langfitt, 1 Jean-Yves Metais, 1 Wenting Zheng, 3 Abishek Vaidya, 1 Janice Riberdy, 1 Sheng Zhou, 4 Paulina Velasquez, 1 Guolian Kang, 5 Robert Throm, 6 Catherine Willis, 2 Clifford Froelich, 2 Jeremy Crawford, 7 Paul Thomas, 7 Benjamin Youngblood, 7 Byoung Ryu, 6 Terrence Geiger, 3 Michael Meagher, 2 Brandon Triplett, 1 Stephen Gottschalk 1 1 Department of Bone Marrow Transplantation and Cellular Therapy, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States; 2 Therapeutics Production and Quality, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States; 3 Depart- ment of Pathology, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States; 4 Experimental Cell Therapeutics Lab, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States; 5 Department of Biostatistics, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States; 6 Vector Development, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States; 7 Department of Immunology, St. Jude Children’s Research Hospital, Memphis, Tennessee, United States Background: Relapsed/refractory CD19-positive acute lympho- blastic leukemia (ALL) has historically been associated with dismal outcomes. CD19-CAR T-cell therapy has shown remarkable effi- cacy in this patient population. However, despite high initial response rates many responses are not durable. Continued explo- ration of the biology of CAR T-cells and its relation to patient outcomes is necessary to optimize the long-term benefits of this therapy. Study Design: We developed a Phase I/II clinical study to evaluate the safety and efficacy of escalating doses of autologous CD19-CAR T-cells in patients 21 years old with relapsed/re- fractory CD19-positive ALL (NCT03573700). The CD19-CAR T-cell product for this study was generated using a lentiviral vector encoding a 2 nd generation CD19-CAR with a 4-1BB.z signaling domain, which was produced by a stable producer cell line. Par- ticipants receive lymphodepleting chemotherapy (fludarabine, 25 mg/m 2 daily x3, and cyclophosphamide, 900 mg/m 2 daily x1), followed by a single infusion of CAR T-cells. Exploratory study objectives seek to provide biologic insights into the epigenetic and expression profiles of CAR T-cells post infusion. Results: Five participants have been enrolled so far. Each received lymphode- pleting chemotherapy and infusion of 1  10 6 CAR T-cells/kg (dose level 1). All patients had expected transient neutropenia/lympho- penia, and 1 patient had grade 1 CRS and neurotoxicity. This pa- tient also had extramedullary disease of his kidney, and experienced a transient grade 3 acute kidney injury. Post-infusion, CAR T-cells expanded in the peripheral blood of all patients (range: 4.92e6.34 log CAR copies/mL), with peak expansion occurring within 2 weeks post-infusion. In the 4 patients who have completed their 4-week post-infusion evaluation, CAR T-cells were present in all bone marrow and CSF samples. Of these patients, 3 achieved a MRD- negative CR. Detailed correlative studies are in progress and, for now, demonstrate that it is feasible to track the transcriptional programs of individual CD19-CAR T-cells post-infusion using 10x single cell RNA seq. Conclusions: The initial clinical experience with our CD19-CAR T-cell product demonstrates an encouraging safety profile, consistent CAR T-cell expansion post-infusion, and anti-ALL activity. Accrual continues, and will include a Phase II expansion cohort to further inform on safety and efficacy. Funding: Research was supported by ALSAC. Keywords: leukemia, CAR, cellular therapy, CAR-T, immunotherapy, CT CT-219 A Prospective Comparison of Un-Manipulated Haploidentical (with PTCY) vs HLA-Identical Sibling Transplants for Different Hematologic Disorders: A Single Center Experience of 82 Patients in a Developing Country Omar Fahmy  , 1 Mohamad Ali, 2 Mahmoud Bokhary, 3 Hossam Kamel, 2 Alaa El-Haddad, 2 Rafat A. Fattah, 2 Mohamad Samra, 2 Gamal Fathy, 3 Maha Farouk 1 1 Department of Medicine, Clinical Hematology Unit, Cairo University, Cairo, Egypt; 2 National Cancer Institute, Cairo University, Cairo, Egypt; 3 Nasser Institute Hospital, Cairo, Egypt Background: Haploidentical stem cell transplantation (HIT) is gaining more popularity when an HLA-matched donor is lacking. Accordingly, we prospectively evaluated the safety and efficacy of the former and compared it to HLA-identical sibling transplants (IST). Design: From June 2015 to April 2018, 82 patients were enrolled (41 patients in each) with almost identical patient char- acteristics (specially age, performance status and disease status at time of transplantation), in the BMT unit of Nasser Institute Hospital, Cairo, Egypt. Patients and Methods: In each cohort, patients had similar number of malignant (AML, ALL, MDS, CML, NHL) and non-malignant (B-Thalassemia Major, SAA, Abstracts Clinical Lymphoma, Myeloma & Leukemia September 2019 - S265